Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
August 23, 2022 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 09, 2022 07:30 ET
|
Sensei Biotherapeutics
- SNS-101 pre-IND feedback received from FDA with program on track for IND filing in first half of 2023 - - New SNS-101 single dose pharmacokinetic data in non-human primates to be presented in the...
Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer
June 01, 2022 07:30 ET
|
Sensei Biotherapeutics
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer,...
Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference
May 25, 2022 07:30 ET
|
Sensei Biotherapeutics
BOSTON, May 25, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 10, 2022 07:30 ET
|
Sensei Biotherapeutics
- SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors - - Cash runway extended into the first quarter of...
Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
March 10, 2022 07:30 ET
|
Sensei Biotherapeutics
- Reported preclinical proof of concept data from TMAb platform demonstrating potent and selective pH-dependent binding to “active” VISTA - - Initiated 2 new therapeutic programs and...
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
March 09, 2022 16:05 ET
|
Sensei Biotherapeutics
BOSTON, March 09, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer,...
Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference
March 03, 2022 07:30 ET
|
Sensei Biotherapeutics
BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit
February 11, 2022 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics Announces Executive Promotions
January 06, 2022 08:00 ET
|
Sensei Biotherapeutics
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...